• By Concept
  • By Last Name
  • By Full Text

Pericak-Vance, Margaret A.

Grant Detail

The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.



Genomic Architecture of Progression and Treatment Response in AMD

15 June 2000 - 31 July 2016
NATIONAL EYE INSTITUTE
Total Funding: $ 5,944,111

FY 2011
2R01EY012118-11
$ 1,377,917
FY 2010
5R01EY012118-10
$ 1,146,506
FY 2010
3R01EY012118-10S1
$ 143,865
FY 2009
5R01EY012118-09
$ 1,137,306
FY 2009
3R01EY012118-09S1
$ 350,000
FY 2008
5R01EY012118-08
$ 671,810
FY 2007
7R01EY012118-07
$ 1,116,707
 
 
$ 5,944,111
Abstract

DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is a significant health problem that affects millions of individuals and is the most common cause of severe vision loss among individuals over age 50 in the U.S. (Rein et al. 2006). The influence of genetic variation on AMD is strong and through the application of recent technological advances the genetic etiology of risk for AMD is being deconstructed. Independent studies, including our own, have identified and confirmed variations in multiple genes that affect risk to AMD, including CFH, HTRA1/ARMS2, C2/CFB, and C3 (DeAngelis et al. 2007;Edwards et al. 2005;Haines et al. 2005;Jakobsdottir et al. 2005;Klein et al. 2005;Maller et al. 2006;Rivera et al. 2005;Schaumberg et al. 2007;Schmidt et al. 2006;Hageman et al. 2005;Yates et al. 2007;Maller et al. 2007). Variation in these genes explain a significant portion of the genetic risk for AMD and ongoing studies are continuing to identify additional such genes. Also important are environmental risk factors such as smoking, hormone therapy and diet that contribute to AMD risk both independently and through their interactions with genes (Schmidt et al. 2006;Schaumberg et al. 2007;Wang et al. 2009). Again, ongoing studies are teasing apart these contributions. However, risk is just one of the many facets of the overall genetic architecture of AMD. Disease progression and treatment response are two critical elements also influenced by genetic variation (Shuler, Jr. et al. 2007;Seddon et al. 2007;Francis et al. 2009). The goal of this proposal is to increase our understanding of the genetic etiology of progression and treatment response in AMD, both of which have been understudied. Identifying the genes underlying clinical outcomes is directly relevant to better directing current treatments and developing new and better treatments and regimens for those suffering this disabling disorder. PUBLIC HEALTH RELEVANCE: Age-related macular degeneration (AMD) is a significant health problem that affects millions of individuals and is the most common cause of severe vision loss among individuals over age 50 in the U.S. The goal of this proposal is to increase our understanding of the genetic etiology of progression and treatment response in AMD, both of which have been understudied. Identifying the genes underlying clinical outcomes is directly relevant to better directing current treatments and developing new and better treatments and regimens for those suffering this disabling disorder.

36 Resulting Publications

Scientific Context

This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.

Related Grants

Related Publications

Related Topics

Appears in this Publication



Related Experts

Author of this Publication

  • Internal Experts
    Publications